Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T in Recurrent/Refractory Neuromyelitis Optica
NCT05828212Phase 1Completed
- Sponsor
- Zhejiang University
- Start
- May 2023
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital) in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Zhejiang University. Primary endpoints: Dose Limited Toxicity at 28 days, Adverse Events and Serious Adverse Events at 2 years and 1 more. Started May 2023; status: completed.
02
Drugs
Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital)
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05828212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828212.